Regorafenib‑induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report

Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH and Zopf D: Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 129:245–255. 2011.PubMed/NCBI View Article : Google Scholar

Krishnamoorthy SK, Relias V, Sebastian S, Jayaraman V and Saif MW: Management of regorafenib-related toxicities: A review. Therap Adv Gastroenterol. 8:285–297. 2015.PubMed/NCBI View Article : Google Scholar

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312. 2013.PubMed/NCBI View Article : Google Scholar

Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, et al: Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 16:619–629. 2015.PubMed/NCBI View Article : Google Scholar

Zhao B and Zhao H: Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib. Oncotarget. 8:93813–93824. 2017.PubMed/NCBI View Article : Google Scholar

Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC and Ferrara N: VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 417:954–958. 2002.PubMed/NCBI View Article : Google Scholar

Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, Bohlen P, Witte L, et al: Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med. 8:841–849. 2002.PubMed/NCBI View Article : Google Scholar

George JN and Aster RH: Drug-induced thrombocytopenia: Pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program 153-158, 2009.

Salib M, Clayden R, Clare R, Wang G, Warkentin TE, Crowther MA, Lim W, Nazi I, Kelton JG and Arnold DM: Difficulties in establishing the diagnosis of immune thrombocytopenia: An agreement study. Am J Hematol. 91:E327–E329. 2016.PubMed/NCBI View Article : Google Scholar

Kelton JG, Vrbensky JR and Arnold DM: How do we diagnose immune thrombocytopenia in 2018? Hematology Am Soc Hematol Educ Program. 2018:561–567. 2018.PubMed/NCBI View Article : Google Scholar

McMillan R, Wang L, Tomer A, Nichol J and Pistillo J: Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 103:1364–1369. 2004.PubMed/NCBI View Article : Google Scholar

Zhang D, Li H, Ma L, Zhang X, Xue F, Zhou Z, Chi Y, Liu X, Huang Y, Yang Y and Yang R: The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia. Autoimmunity. 47:519–529. 2014.PubMed/NCBI View Article : Google Scholar

Zhang JM, Feng FE, Wang QM, Zhu XL, Fu HX, Xu LP, Liu KY, Huang XJ and Zhang XH: Platelet-derived growth factor-BB protects mesenchymal stem cells (MSCs) derived from immune thrombocytopenia patients against apoptosis and senescence and maintains MSC-mediated immunosuppression. Stem Cells Transl Med. 5:1631–1643. 2016.PubMed/NCBI View Article : Google Scholar

Radwi M and Cserti-Gazdewich C: Drug-induced immune thrombocytopenia associated with use of tyrosine kinase inhibitor imatinib. J Taibah University Med Sci. 10:365–368. 2015.

Ansari Z and George MK: Drug-induced immune-mediated thrombocytopenia secondary to sunitinib in a patient with metastatic renal cell carcinoma: A case report. J Med Case Rep. 7(54)2013.PubMed/NCBI View Article : Google Scholar